Last reviewed · How we verify
L-T4+T3 (thyroid tablet)
L-T4+T3 (thyroid tablet) is a Thyroid hormone replacement therapy Small molecule drug developed by Zhongshan Hospital Xiamen University. It is currently FDA-approved for Hypothyroidism, Thyroid hormone replacement after thyroidectomy or radioactive iodine therapy.
L-T4+T3 combination therapy replaces deficient thyroid hormones by providing both levothyroxine (T4) and liothyronine (T3) to restore normal thyroid hormone levels.
L-T4+T3 is a thyroid tablet that has been studied in various clinical trials for conditions such as hypothyroidism, thyroid cancer, and heart failure with reduced ejection fraction. The tablet is not a performance-enhancing substance, as it is not listed among the interventions in the clinical trials on ClinicalTrials.gov.
At a glance
| Generic name | L-T4+T3 (thyroid tablet) |
|---|---|
| Sponsor | Zhongshan Hospital Xiamen University |
| Drug class | Thyroid hormone replacement therapy |
| Target | Thyroid hormone receptors (TR-alpha, TR-beta) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Levothyroxine (L-T4) is converted peripherally to the active form T3 and acts as a pro-hormone, while liothyronine (T3) is the active thyroid hormone that directly binds thyroid hormone receptors in target tissues. Together, they restore euthyroid state by activating nuclear thyroid hormone receptors, which regulate metabolism, energy production, and cardiovascular function. This combination approach aims to more closely mimic natural thyroid hormone physiology compared to T4 monotherapy.
Approved indications
- Hypothyroidism
- Thyroid hormone replacement after thyroidectomy or radioactive iodine therapy
Common side effects
- Palpitations
- Tremor
- Anxiety
- Insomnia
- Heat intolerance
- Tachycardia
Key clinical trials
- T4/T3 Therapy in Hypothyroidism (PHASE2)
- Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy
- Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery (PHASE3)
- LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism. (PHASE3)
- Developing Oral LT3 Therapy for Heart Failure - HFpEF (PHASE1, PHASE2)
- Developing Oral LT3 Therapy for Heart Failure - HFrEF (PHASE1, PHASE2)
- Energy Metabolism in Thyroidectomized Patients (PHASE2)
- Efficacy of Thyroid Hormone Replacement for Secondary Hypothyroidism Following Intracerebral Hemorrhage (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-T4+T3 (thyroid tablet) CI brief — competitive landscape report
- L-T4+T3 (thyroid tablet) updates RSS · CI watch RSS
- Zhongshan Hospital Xiamen University portfolio CI
Frequently asked questions about L-T4+T3 (thyroid tablet)
What is L-T4+T3 (thyroid tablet)?
How does L-T4+T3 (thyroid tablet) work?
What is L-T4+T3 (thyroid tablet) used for?
Who makes L-T4+T3 (thyroid tablet)?
What drug class is L-T4+T3 (thyroid tablet) in?
What development phase is L-T4+T3 (thyroid tablet) in?
What are the side effects of L-T4+T3 (thyroid tablet)?
What does L-T4+T3 (thyroid tablet) target?
Related
- Drug class: All Thyroid hormone replacement therapy drugs
- Target: All drugs targeting Thyroid hormone receptors (TR-alpha, TR-beta)
- Manufacturer: Zhongshan Hospital Xiamen University — full pipeline
- Therapeutic area: All drugs in Endocrinology
- Indication: Drugs for Hypothyroidism
- Indication: Drugs for Thyroid hormone replacement after thyroidectomy or radioactive iodine therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing